Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.

Image courtesy of Shutterstock

The Jenner Institute at Oxford University, together with partners Imaxio and GSK, has started a phase I clinical trial of a novel vaccine candidate aimed at blocking transmission of malaria.

Around half the world’s population is at risk of malaria and the disease led to an estimated 584,000 deaths in 2013.  MosquirixTM, a malaria vaccine candidate developed by GSK, has just received a positive scientific opinion from the European Medicines Agency for use in young children.  MosquirixTM aims at addressing the objectives set for a first generation vaccine in the WHO malaria vaccine technology roadmap. The roadmap also outlines ambitious goals for second generation vaccines including transmission-blocking vaccines. The latter prevent mosquitoes from transmitting malaria to non-infected persons.

Read more